Vazquez RM et al: Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Exp Rev Gastroenterol Hepatol 2011;5:301.
Basch E et al: Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2011;29:4189.
Ettinger DS et al: Antiemesis. J Natl Canc Comp Netw 2012;10:456.
Jordan K et al: Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): A comprehensive review. Ann Oncol 2015; 26:1081.
Navarri R et al: Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 2016;374:1356.
Navarri R et al: Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016;375:134.
Bloomgren G et al: Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:20.
Bressler B et al: Clinical guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto consensus. Gastroenterology 2015;148:1035.
Casteelle N et al: Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320.
Cheifetz AS et al: Management of active Crohn disease. JAMA 2013;309:2150.
Ford AC et al: Efficacy of biological therapies in inflammatory bowel disease: A systematic review and meta-analysis. Am J Gastroenterol 2011;106:644.
Ford A et al: Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates in ulcerative colitis: A systematic review and meta-analysis. Am J Gastroenterol 2012;107:167.
Ford A et al: Ulcerative colitis. BMJ 2013;346:f432.
Kotlyar DS et al: Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: A meta-analysis. Clin Gastroenterol Hepatol 2015;13:847.
Mosli MH et al: Vedolizumab for induction and maintenance of remission in ulcerative colitis: A Cochrane systematic review and meta-analysis. Inflamm
Bowel Dis 2015;21:1151.
Ordas I: Ulcerative colitis. Lancet 2012;380:1606.
Pola S et al: Strategies for the care of adults hospitalized for active ulcerative colitis.
Clin Gastroenterol Hepatol 2012;10:1315.
Sandborn WJ et al: Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257.
Sandborn WJ et al: Subcutaneous golimumab induces clinical response and remission in patients with moderate to severe ulcerative colitis. Gastroenterology 2014;146:85.